Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force

Angiogenic endothelial cells and tumour cells can survive under hypoxic conditions and even proliferate and migrate in a low‐oxygen environment. In both cell types, high rates of glycolysis (i.e. conversion of glucose to lactate) and glutaminolysis provide most of the required biosynthetic intermediates and energy to support sprouting and cell division without coupling to oxidative phosphorylation. This metabolic preference is observed under hypoxic conditions, but also in situations in which oxygen is present. In the case of tumour cells, this is known as the Warburg effect and is largely governed by oncogenes. In endothelial cells lining tumour blood vessels, the option of respiration‐independent metabolism allows the neovasculature to resist the hostile environment of fluctuating oxygen tension (ranging from severe hypoxia to quasi‐normal levels of oxygen). In addition, accumulation in tumours of lactate, the end‐product of glycolysis, largely contributes to the angiogenic phenotype through inhibition of prolyl hydroxylase 2 and the activation of HIF1α and NFκB. Activation of the latter in a hypoxia‐independent manner leads to the increased production of interleukin‐8/CXCL8 which drives the autocrine stimulation of endothelial cell proliferation and maturation of neovessels. In conclusion, the addiction of proliferating endothelial cells for glucose and glutamine as fuels and the driving force of lactate to promote angiogenesis provide novel potential treatment options without the disadvantages of conventional anti‐angiogenic drugs.

[1]  Mark W. Dewhirst,et al.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.

[2]  Robert S. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[3]  R. Boidot,et al.  Identification of Cyclooxygenase-2 as a Major Actor of the Transcriptomic Adaptation of Endothelial and Tumor Cells to Cyclic Hypoxia: Effect on Angiogenesis and Metastases , 2010, Clinical Cancer Research.

[4]  M. Dewhirst,et al.  Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis , 2012, PloS one.

[5]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[6]  Julien Verrax,et al.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.

[7]  Bruce Klitzman,et al.  Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. , 2006, Cancer research.

[8]  Franziska Hirschhaeuser,et al.  Lactate: a metabolic key player in cancer. , 2011, Cancer research.

[9]  J. Nielsen,et al.  Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Curi,et al.  Maximum activities of some key enzymes of glycolysis, glutaminolysis, Krebs cycle and fatty acid utilization in bovine pulmonary endothelial cells , 1987, FEBS letters.

[11]  Shankar C. Sanka,et al.  Vacuolar-type H+-ATPases at the plasma membrane regulate pH and cell migration in microvascular endothelial cells. , 2006, American journal of physiology. Heart and circulatory physiology.

[12]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[13]  V. Grégoire,et al.  Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. , 2006, Cancer research.

[14]  S. Richard,et al.  Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia , 2012, Haematologica.

[15]  B. Reglin,et al.  Structural response of microcirculatory networks to changes in demand: information transfer by shear stress. , 2003, American journal of physiology. Heart and circulatory physiology.

[16]  C. Dalgard,et al.  Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1* , 2005, Journal of Biological Chemistry.

[17]  J. Esplugues,et al.  Regulation of Oxygen Distribution in Tissues by Endothelial Nitric Oxide , 2009, Circulation research.

[18]  T. Copetti,et al.  Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review , 2011, Front. Pharmacol..

[19]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[20]  K. Bennewith,et al.  Quantifying Transient Hypoxia in Human Tumor Xenografts by Flow Cytometry , 2004, Cancer Research.

[21]  S. Weinhouse On respiratory impairment in cancer cells. , 1956, Science.

[22]  Frederik De Smet,et al.  Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.

[23]  J. Nielsen,et al.  Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity , 2006, Proceedings of the National Academy of Sciences.

[24]  W. Zwerschke,et al.  Premature senescence of human endothelial cells induced by inhibition of glutaminase , 2008, Biogerontology.

[25]  E. Rofstad,et al.  Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis , 2007, Clinical Cancer Research.

[26]  S. Bonhoeffer,et al.  Cooperation and Competition in the Evolution of ATP-Producing Pathways , 2001, Science.

[27]  M. Dewhirst,et al.  Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.

[28]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[29]  C. Dessy,et al.  Vascular Hypoxic Preconditioning Relies on TRPV4-Dependent Calcium Influx and Proper Intercellular Gap Junctions Communication , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[30]  V. Grégoire,et al.  Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery , 2006, Molecular Cancer Therapeutics.

[31]  O. Féron Challenges in Pharmacology of Anti-Cancer Drugs – The Search for Addictions , 2010, Front. Pharm..

[32]  G. Breier,et al.  Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. , 2011, Cancer research.

[33]  Peter Carmeliet,et al.  Regulation of angiogenesis by oxygen and metabolism. , 2009, Developmental cell.

[34]  James B. Mitchell,et al.  Imaging cycling tumor hypoxia. , 2010, Cancer research.

[35]  A. Giaccia,et al.  PHD2 in tumour angiogenesis , 2010, British Journal of Cancer.

[36]  Benoit Macq,et al.  Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? , 2004, Physics in medicine and biology.

[37]  O. Feron,et al.  Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments , 2011, Disease Models & Mechanisms.

[38]  O. Feron,et al.  Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  O. Barbash,et al.  Expression of Angiogenic Factors Vascular Endothelial Growth Factor and Interleukin-8/CXCL8 Is Highly Responsive to Ambient Glutamine Availability , 2004, Cancer Research.

[40]  Tim Crook,et al.  The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia , 2010, European journal of haematology.

[41]  Richard P. Hill,et al.  Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma , 2004, Cancer Research.

[42]  C. Dessy,et al.  Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. , 2012, Cancer research.

[43]  Pierre Sonveaux,et al.  Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.

[44]  D. Yellon,et al.  The therapeutic potential of ischemic conditioning: an update , 2011, Nature Reviews Cardiology.

[45]  William C. Aird,et al.  Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms , 2007, Circulation research.

[46]  Howard Y. Chang,et al.  Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. , 2009, Cancer cell.

[47]  B. Gallez,et al.  Nitric oxide delivery to cancer: why and how? , 2009, European journal of cancer.

[48]  E. Rofstad,et al.  Fluctuations in tumor blood perfusion assessed by dynamic contrast‐enhanced MRI , 2007, Magnetic resonance in medicine.

[49]  J. Balligand,et al.  eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. , 2009, Physiological reviews.